MAIA Biotechnology (MAIA) Other Accumulated Expenses (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Other Accumulated Expenses of $325662.0 for Q1 2026, up 5.3% year-over-year from $309257.0 in Q1 2025, and up 31.28% quarter-over-quarter from $248066.0 in Q4 2025.
MAIA Biotechnology (MAIA) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Other Accumulated Expenses for 6 consecutive years, with $325662.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 5.3% year-over-year to $325662.0; the TTM figure through Mar 2026 stood at $325662.0 (up 5.3% YoY), while the FY2025 annual figure was $248066.0, up 13.88% from the prior year.
- Other Accumulated Expenses rose to $325662.0 in Q1 2026 per MAIA's latest filing, from $248066.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $610393.0 in Q4 2023 and bottomed at $32594.0 in Q3 2022.
- Historically, Other Accumulated Expenses has averaged $272828.6 across 5 years, with a median of $284471.5 in 2024.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses surged 1157.81% — and 2024, when it tumbled 64.31%.
- MAIA Biotechnology's Other Accumulated Expenses stood at $159269.0 in 2022, then surged by 283.25% to $610393.0 in 2023, then sank by 64.31% to $217832.0 in 2024, then advanced by 13.88% to $248066.0 in 2025, then jumped by 31.28% to $325662.0 in 2026.
- Business Quant data shows MAIA's Other Accumulated Expenses at $325662.0 in Q1 2026, $248066.0 in Q4 2025, and $341187.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 366,044.00 |
| Mar 31, 2026 | 325,662.00 |
| Dec 31, 2025 | 248,066.00 |
| Sep 30, 2025 | 341,187.00 |
| Jun 30, 2025 | 346,538.00 |
| Mar 31, 2025 | 309,257.00 |
| Dec 31, 2024 | 217,832.00 |
| Sep 30, 2024 | 313,878.00 |
| Jun 30, 2024 | 317,129.00 |
| Mar 31, 2024 | 259,686.00 |
| Dec 31, 2023 | 610,393.00 |
| Sep 30, 2023 | 409,971.00 |
| Jun 30, 2023 | 197,211.00 |
| Mar 31, 2023 | 162,251.00 |
| Dec 31, 2022 | 159,269.00 |
| Sep 30, 2022 | 32,594.00 |
| Jun 30, 2022 | 114,333.00 |
| Dec 31, 2021 | 111,271.00 |